Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a Cancer Journal for Clinicians. 2021;71:7-33.

Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, et al. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET/MRI. Eur J Nuclear Med Molecular Imag. 2021;48:1795–805.

Article  CAS  Google Scholar 

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urology. 2016;70:926–37.

Article  Google Scholar 

Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, et al. The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nuclear Med Molecular Imaging. 2017;44:1806–12.

Article  Google Scholar 

Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology. 2018;286:186–95.

Article  PubMed  Google Scholar 

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol: official J Ame Soc Clin Oncol. 2018;36:1080–7.

Article  CAS  Google Scholar 

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.

Article  CAS  PubMed  Google Scholar 

Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nuclear Med : official public, Soc Nuclear Med. 2022;63:59–68.

Article  CAS  Google Scholar 

Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res : an official J Ame Assoc Cancer Res. 2019;25:7448–54.

Article  CAS  Google Scholar 

Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A Prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res : official J Ame Assoc Cancer Res. 2020;26:4551–8.

Article  CAS  Google Scholar 

Pan J, Wei Y, Zhang T, Liu C, Hu X, Zhao J, et al. Stereotactic radiotherapy for lesions detected via (68)Ga-prostate-specific membrane antigen and (18)F-fluorodexyglucose positron emission tomography/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urology Oncol. 2022;5:420–7.

Article  Google Scholar 

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, et al. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. BMC Cancer. 2015;15:420.

Article  PubMed  PubMed Central  Google Scholar 

Laudicella R, Rüschoff JH, Ferraro DA, Brada MD, Hausmann D, Mebert I, et al. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. Eur J Nuclear Med Molecular Imaging. 2022;49:3917–28.

Article  CAS  Google Scholar 

Liberini V, Laudicella R, Balma M, Nicolotti DG, Buschiazzo A, Grimaldi S, et al. Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics. Eur Radio Exp. 2022;6:27.

Article  Google Scholar 

Alongi P, Laudicella R, Stefano A, Caobelli F, Comelli A, Vento A, et al. Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So. 2022;66:352-60.